Search Results for "Neoadjuvant Therapy For Oab"
Original Source: Astellas wins FDA approval for overactive bladder therapy
Astellas Pharma has gained FDA approval for Myrbetriq (mirabegron) extended-release tablets for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.
Matching Channels
Neoadjuvant therapy is the administration of therapeutic agents before the main treatment. One example is neoadjuvant hormone therapy prior to radical radiotherapy for adenocarcinoma of the prostate...
Matching News
Neoadjuvant Hormone Therapy in Radical Prostatectomy
Can neoadjuvant hormonal therapy positively impact the outcome of laparoscopic radical prostatectomy? BMC Urology
Fine-Tuning Neoadjuvant Therapy in Breast Cancer
Drs. Ian Smith and Fabrice André highlight the breast cancer sessions from ESMO 2012, focusing on neoadjuvant therapy and the introduction of a novel agent that shows significant antitumor activity....
Biliary tract: Is there a role for neoadjuvant and adjuvant therapy in biliary cancer?
A retrospective analysis of adjuvant and neoadjuvant therapy in patients with resectable biliary tract adenocarcinoma shows they confer no survival advantage in the treated groups, leading the authors...
PET and CT can't show response to neoadjuvant therapy of rectal CA
NEW YORK (Reuters Health) - After neoadjuvant chemoradiation for locally advanced rectal cancer, PET and CT scans aren't accurate enough to detect a pathological complete response, according to a...
By digital profiling of residual breast tumors after neoadjuvant therapy, the authors identify gene expression patterns that correspond with a higher risk of metastasis and recurrence. Activation of t...
Rectal CA recurs similarly after short- or long-course neoadjuvant radiation
NEW YORK (Reuters Health) - In a recent study of patients with stage T3 rectal cancer, neoadjuvant short-course radiation plus postop chemotherapy didn't prevent recurrence any better than a longe...
Six months of neoadjuvant treatment with the targeted agent Zytiga® (abiraterone) plus hormonal therapy eliminated or nearly eliminated tumors in one-third of men with localized high-risk prostate ca...
Neoadjuvant Chemotherapy More Suitable For Breast Cancer Patients Who Lack RB Gene
Breast cancer patients whose tumors lacked the retinoblastoma tumor suppressor gene (RB) had an improved pathological response to neoadjuvant chemotherapy, researchers at Thomas Jefferson University H...
Matching PubMed Articles
Controversies Concerning the Use of Neoadjuvant Systemic Therapy for Primary Breast Cancer.
The major aim of neoadjuvant systemic therapy is to improve prognosis by individualizing treatment. The proven benefits of neoadjuvant systemic therapy include reducing tumor burden, higher breast-con...
BACKGROUND: Consensus guidelines recommend neoadjuvant therapy in locally advanced esophageal cancer; however, whether this recommendation has been widely adopted is unknown. Therefore, we evaluated t...
Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma.
Neoadjuvant therapy has been used to improve survival in operable pancreatic cancer. The authors' objective was to compare long-term outcomes in patients receiving neoadjuvant versus adjuvant therapy...
Current state of neoadjuvant therapy of soft tissue sarcoma.
The treatment of soft tissue sarcoma is clinically challenging. Referral to an experienced center with an interdisciplinary team is strongly recommended. Neoadjuvant therapy, including irradiation and...
Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.
Neoadjuvant endocrine therapy has been increasingly employed in clinical practice to improve surgical options for postmenopausal women with bulky hormone receptor-positive breast cancer. Recent studie...
